TCL Archive FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview. November 7, 2003
TCL Archive NCI, IOM Called To Congress to Explain Divergent Positions On Minority Research January 29, 1999
TCL Archive FTC Report Disagrees With Key Provision Of Biologics Bill Backed By Companies June 12, 2009
